title: Resveratrol and its oligomers: modulation of sphingolipid metabolism and signaling in disease.
abstract: Resveratrol, a natural compound endowed with multiple health-promoting effects, has received much attention given its potential for the treatment of cardiovascular, inflammatory, neurodegenerative, metabolic and age-related diseases. However, the translational potential of resveratrol has been limited by its specificity, poor bioavailability and uncertain toxicity. In recent years, there has been an accumulation of evidence demonstrating that resveratrol modulates sphingolipid metabolism. Moreover, resveratrol forms higher order oligomers that exhibit better selectivity and potency in modulating sphingolipid metabolism. This review evaluates the evidence supporting the modulation of sphingolipid metabolism and signaling as a mechanism of action underlying the therapeutic efficacy of resveratrol and oligomers in diseases, such as cancer.
authors.affiliation: Cell Biology and Drug Discovery and Design Groups, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, G4 0RE, UK, limkg@gis.a-star.edu.sg.
authors.forename: Keng Gat
authors.initials: KG
authors.lastname: Lim
authors.forename: Alexander I
authors.initials: AI
authors.lastname: Gray
authors.forename: Nahoum G
authors.initials: NG
authors.lastname: Anthony
authors.forename: Simon P
authors.initials: SP
authors.lastname: Mackay
authors.forename: Susan
authors.initials: S
authors.lastname: Pyne
authors.forename: Nigel J
authors.initials: NJ
authors.lastname: Pyne
mesh_terms: D000818:Animals; D000972:Antineoplastic Agents, Phytogenic / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity; D017209:Apoptosis / Q000187:drug effects; D001665:Binding Sites; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D055808:Drug Discovery; D006801:Humans; D062105:Molecular Docking Simulation; D015394:Molecular Structure; D009369:Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D019636:Neurodegenerative Diseases / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D000077185:Resveratrol; D015398:Signal Transduction; D013107:Sphingolipids / Q000378:metabolism*; D013267:Stilbenes / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use* / Q000633:toxicity
chemical_list: D000972:Antineoplastic Agents, Phytogenic; D013107:Sphingolipids; D013267:Stilbenes; D000077185:Resveratrol